Sacituzumab Govitecan-Hziy (Trodelvy)

Sacituzumab govitecan-hziy (Trodelvy™) was an antibody-drug conjugate approved for treating adult patients with metastatic triple-negative breast cancer (TNBC) who had previously received two or more therapies. It worked by targeting Trop-2 receptors on cancer cells, delivering the topoisomerase inhibitor SN-38 to induce cell death. The approval was based on the IMMU-132-01 Phase I/II trial, which included 108 patients with metastatic TNBC, showing an overall response rate of 33.3%. Common side effects included nausea, diarrhea, neutropenia, and alopecia. The drug required premedication to prevent infusion reactions and chemotherapy-induced nausea. It had a boxed warning for severe neutropenia and diarrhea, and patients with the UGT1A1∗28 allele were at increased risk for adverse reactions. Ongoing studies were exploring its use in other cancers and in combination with other therapies.